Silvia Antolín

2.9k total citations
55 papers, 452 citations indexed

About

Silvia Antolín is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Silvia Antolín has authored 55 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 28 papers in Cancer Research and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Silvia Antolín's work include Breast Cancer Treatment Studies (23 papers), HER2/EGFR in Cancer Research (19 papers) and Cancer Treatment and Pharmacology (17 papers). Silvia Antolín is often cited by papers focused on Breast Cancer Treatment Studies (23 papers), HER2/EGFR in Cancer Research (19 papers) and Cancer Treatment and Pharmacology (17 papers). Silvia Antolín collaborates with scholars based in Spain, United States and Germany. Silvia Antolín's co-authors include Lourdes Calvo, Eva Carrasco, Manuel Valladares‐Ayerbes, Luis Antón-Aparicio, Mar Haz‐Conde, M. Blanco, Isabel Santamarina, María José Lorenzo-Patiño, Angélica Figueroa and Federico Rojo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Silvia Antolín

50 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Silvia Antolín Spain 12 260 201 179 76 54 55 452
Mai Tomiguchi Japan 12 146 0.6× 272 1.4× 280 1.6× 80 1.1× 37 0.7× 24 490
Carla Strina Italy 10 242 0.9× 125 0.6× 107 0.6× 71 0.9× 59 1.1× 25 362
Tatiana S. Gerashchenko Russia 12 226 0.9× 160 0.8× 188 1.1× 92 1.2× 31 0.6× 37 502
Elena Shagisultanova United States 13 220 0.8× 131 0.7× 202 1.1× 118 1.6× 21 0.4× 35 451
Steffen Dickopf Germany 6 218 0.8× 175 0.9× 276 1.5× 51 0.7× 68 1.3× 9 459
Matthias Sommer United States 10 223 0.9× 115 0.6× 416 2.3× 55 0.7× 101 1.9× 14 639
EP Winer United States 11 483 1.9× 173 0.9× 73 0.4× 136 1.8× 74 1.4× 50 563
Kateřina Bouchalová Czechia 12 229 0.9× 128 0.6× 193 1.1× 62 0.8× 31 0.6× 35 486
Mikhail Byakhov Russia 6 221 0.8× 231 1.1× 94 0.5× 52 0.7× 29 0.5× 19 385
Daniela Morales-Espinosa Spain 12 276 1.1× 155 0.8× 206 1.2× 190 2.5× 26 0.5× 25 534

Countries citing papers authored by Silvia Antolín

Since Specialization
Citations

This map shows the geographic impact of Silvia Antolín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Antolín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Antolín more than expected).

Fields of papers citing papers by Silvia Antolín

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Antolín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Antolín. The network helps show where Silvia Antolín may publish in the future.

Co-authorship network of co-authors of Silvia Antolín

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Antolín. A scholar is included among the top collaborators of Silvia Antolín based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Antolín. Silvia Antolín is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
González, Paula, et al.. (2025). Effect of Gender on Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Real-World Study. Biomedicines. 13(2). 437–437. 1 indexed citations
2.
Ayala, Francisco, Silvia Antolín, Joaquín Gavilá Gregori, et al.. (2023). SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). Clinical & Translational Oncology. 25(9). 2647–2664. 14 indexed citations
3.
Antolín, Silvia, Santiago Escrivá-de-Romaní, Pablo Tolosa, et al.. (2023). Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study). Cancer Treatment and Research Communications. 37. 100772–100772.
4.
5.
Pértega-Díaz, Sónia, et al.. (2023). Foot health and quality of life in women with breast cancer undergoing chemotherapy: a cross‐sectional study. Journal of Foot and Ankle Research. 16(1). 52–52.
6.
López‐Tarruella, Sara, Agostina Stradella, Silvia Antolín, et al.. (2023). 406P Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC. Annals of Oncology. 34. S353–S353. 2 indexed citations
7.
Ocaña, Alberto, Marta Gil-Martín, Silvia Antolín, et al.. (2019). Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. Breast Cancer Research and Treatment. 174(3). 693–701. 36 indexed citations
8.
Chacón, José Ignacio, Luis de la Cruz‐Merino, Joaquín Gavilá Gregori, et al.. (2019). SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clinical & Translational Oncology. 21(1). 31–45. 13 indexed citations
9.
Novoa, Alejandra García, et al.. (2018). Angiosarcoma radioinducido de mama en paciente con síndrome de Li-Fraumeni. Cirugía Española. 97(2). 114–116. 4 indexed citations
10.
Borrego, Manuel Ruíz, Marta Gil-Martín, Silvia Antolín, et al.. (2017). A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Annals of Oncology. 28. v75–v75. 1 indexed citations
11.
Cueva, Juan, Silvia Antolín, Lourdes Calvo, et al.. (2017). Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention. Clinical & Translational Oncology. 19(9). 1067–1078. 10 indexed citations
12.
13.
Martín, Miguel, Manuel Ruíz‐Borrego, José M. Pérez, et al.. (2016). A phase I study of sonidegib (S) in combination with docetaxel (D) in patients (pts) with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study). Annals of Oncology. 27. vi87–vi87. 3 indexed citations
14.
Antolín, Silvia, Lourdes Calvo, M. Blanco, et al.. (2015). Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer. 15(1). 297–297. 78 indexed citations
15.
Luque, M., Juan Cueva, Paula García‐Teijido, et al.. (2013). Breast cancer management in the elderly. Clinical & Translational Oncology. 16(4). 351–361. 7 indexed citations
16.
Nebril, Benigno Acea, et al.. (2011). Propuesta de una nueva estrategia terapéutica multidisciplinar en la mujer con cáncer de mama y afectación del ganglio centinela. Cirugía Española. 90(10). 626–633. 4 indexed citations
17.
Antolín, Silvia, et al.. (2011). A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study. Clinical & Translational Oncology. 13(9). 686–691. 3 indexed citations
18.
19.
Antolín, Silvia, et al.. (2010). Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine. Clinical & Translational Oncology. 12(6). 450–452. 2 indexed citations
20.
Calvo, Lourdes, et al.. (2006). Subacute Cerebellar Degeneration as Paraneoplastic Syndrome: Initial Symptom of Breast Cancer with HER2 Overexpression. Clinical Breast Cancer. 7(1). 79–80. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mai Tomiguchi Breakdown of academic impact, for papers by Carla Strina Breakdown of academic impact, for papers by Tatiana S. Gerashchenko Breakdown of academic impact, for papers by Elena Shagisultanova Breakdown of academic impact, for papers by Steffen Dickopf Breakdown of academic impact, for papers by Matthias Sommer Breakdown of academic impact, for papers by EP Winer Breakdown of academic impact, for papers by Kateřina Bouchalová Breakdown of academic impact, for papers by Mikhail Byakhov Breakdown of academic impact, for papers by Daniela Morales-Espinosa
Rankless by CCL
2026